Cargando…
FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer
Anti-EGFR monoclonal antibodies (mAb) such as cetuximab, panitumumab are one kind of efficacious targeted drugs in treatment of metastatic colorectal cancer (mCRC). However, only a small proportion of patients harbored wild-KRAS genotype can benefit from it. We hypothesized that personal genetic het...
Autores principales: | Ying, Hou-Qun, Wang, Feng, Chen, Xiao-Lin, He, Bang-Shun, Pan, Yu-Qin, Chen, Jie, Liu, Xian, Cao, Wei-Jun, Peng, Hong-Xin, Lin, Kang, Wang, Shu-Kui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695045/ https://www.ncbi.nlm.nih.gov/pubmed/26363448 |
Ejemplares similares
-
Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis
por: Morgan, Ann W, et al.
Publicado: (2006) -
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2014) -
Single Nucleotide Polymorphism rs10919543 in FCGR2A/FCGR3A Region Confers Susceptibility to Takayasu Arteritis in Chinese Population
por: Qin, Fang, et al.
Publicado: (2016) -
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
por: Magnes, T., et al.
Publicado: (2019) -
Association of FCGR3A and FCGR3B haplotypes with rheumatoid arthritis and primary Sjögren's syndrome
por: Mackie, S, et al.
Publicado: (2005)